Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $27.5100 (1.31%) ($27.2000 - $28.1300) on Thu. Nov. 12, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.43% (three month average) | RSI | 53 | Latest Price | $27.5100(1.31%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 3.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.715% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) TBT(-2%) EDOC(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.715% (StdDev 3.43%) | Hourly BBV | -0.8 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $27.97(-1.64%) | 10 Day Moving Average | $27.6(-0.33%) | 20 Day Moving Average | $27.5(0.04%) | To recent high | -11.6% | To recent low | 44.6% | Market Cap | $3.484b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |